Volume 26, Number 8—August 2020
Research
Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States
Manish Patel
, Jufu Chen, Sara Kim, Shikha Garg, Brendan Flannery, Zaid Haddadin, Danielle Rankin, Natasha Halasa, H. Keipp Talbot, and Carrie Reed
, Jufu Chen, Sara Kim, Shikha Garg, Brendan Flannery, Zaid Haddadin, Danielle Rankin, Natasha Halasa, H. Keipp Talbot, and Carrie Reed
Table 5
Acute respiratory illness hospitalizations for patientsby age who had immunosuppressive conditions in MarketScan database, United States, July 2012–August 2017*
| Characteristic | All ARI hospitalizations |
ARI hospitalizations in immunosuppressed persons† |
ARI in immunosuppressed versus nonimmunosuppressed persons, relative rate/1,000 person-years (95% CI)‡ | |||
|---|---|---|---|---|---|---|
| No. | Rate/1,000 person-years | No. (%) | Rate/1,000 person-years | |||
| Year round, August–July | ||||||
| Age, y | ||||||
| All | 542,105 | 4.7 | 173,665 (32.0) | 25.5 | 4.2 (4.0–4.3) | |
| >1–8 | 50,170 | 4.5 | 6,638 (13.2) | 41.2 | 8.1 (7.8–8.4) | |
| 9–17 | 14,388 | 1.1 | 2,839 (19.7) | 6.0 | 5.0 (4.7–5.4) | |
| 18–49 | 88,051 | 1.7 | 29,136 (33.1) | 11.3 | 6.7 (6.5–6.9) | |
| 50–64 | 142,631 | 5.0 | 57,512 (40.3) | 23.3 | 4.8 (4.6–4.9) | |
| >65 |
246,865 |
26.2 |
77,540 31.4) |
68.3 |
2.1 (2.0–2.1) |
|
| Peak influenza season, December–March | ||||||
| Age, y | ||||||
| All | 240,856 | 6.3 | 77,308 (32.1) | 34.0 | 4.3 (4.2–4.5) | |
| <1–8 | 27,084 | 7.3 | 3,408 (12.6) | 63.4 | 7.9 (7.5–8.3) | |
| 9–17 | 5,838 | 1.3 | 1,258 (21.5) | 7.9 | 5.7 (5.1–6.4) | |
| 18–49 | 37,190 | 2.1 | 12,786 (34.4) | 14.8 | 6.8 (6.8–7.4) | |
| 50–64 | 61,316 | 6.4 | 25,491 (41.6) | 31.0 | 5.0 (4.8–5.2) | |
| >65 | 109,428 | 34.9 | 34,365 (31.4) | 90.8 | 2.1 (2.0–2.2) | |
*ARI, acute respiratory illness.
†See Figure 1. Immunosuppressive denotes patients had International Classification of Diseases codes for either 3 immunosuppressive conditions OR 3 conditions plus immunosuppressive pharmacologic treatment (chemotherapeutic agents or immune modulators or systemic corticosteroids >14 d).
‡Relative rates of ARI were adjusted for year of hospitalization and sex.
Page created: April 29, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.